TEVA - Teva Pharmaceutical Industries Limited
| Previous Close | 21.09 |
| Open | 21.19 |
| Bid | 21.13 x 1100 |
| Ask | 21.14 x 3000 |
| Day's Range | 21.07 - 21.22 |
| 52 Week Range | 10.85 - 33.82 |
| Volume | 4,342,709 |
| Avg. Volume | 11,274,553 |
| Market Cap | 21.515B |
| Beta | 1.01 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -16.26 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | 2017-11-27 |
| 1y Target Est | 19.44 |
Market Realist•5 hours agoRoche’s Blockbuster Drug: Rituxan and Avastin in Q1 2018
Roche’s (RHHBY) MabThera/Rituxan reported revenues of 1.7 billion Swiss francs in the first quarter compared to 1.9 billion Swiss francs in the first quarter of 2017, which reflected a decline of ~8% YoY (year-over-year) on constant exchange rate basis.
- Benzinga•3 days ago
Cantor Fitzgerald: 18 Drug Companies With Catalysts Worth Watching
The biotech analysts at Cantor Fitzgerald have a packed calendar: here are some of the dates they’re tracking and why they’re important. Mallinckrodt PLC (NYSE: MNK ) is expected to release Phase 4 interim ...
- Business Wire•4 days ago
CORRECTING and REPLACING Teva Announces Publication of Phase III Trial Data of Fremanezumab for the Preventive Treatment of Episodic Migraine in the Journal of the American Medical Association
First bulleted paragraph, second sentence of release dated May 15, 2018 should contain the numbers 4.9, 5.3 and 6.5 . Third bulleted paragraph, second sentence, the first number should read 4.4 , and the final number should read 5.8 . Fourth paragraph, third sentence should read ...38.0, 41.7, and 37.3...
- Zacks•4 days ago
Pharma Stock Roundup: Zoetis to Buy Abaxis, NVS Gets FDA Nod for Migraine Drug
Novartis' (NVS) CGRP antibody, Aimovig gains FDA approval for prevention of migraine. Zoetis (ZTS) and Lilly (LLY) announce deals to buy smaller companies.
- Zacks•4 days ago
Amgen's Migraine Drug Aimovig Gets FDA Approval, Shares Up
Amgen's (AMGN) preventive treatment for migraine, Aimovig, gets approval in the United States.
- ACCESSWIRE•4 days ago
Free Stock Performance Review on Teva Pharma and Three Other Healthcare Sector
WallStEquities.com has initiated research reports on the following Healthcare stocks: Novartis AG (NYSE: NVS), Teva Pharmaceutical Industries Ltd (NYSE: TEVA), GlaxoSmithKline PLC (NYSE: GSK), and Synergy Pharmaceuticals Inc. (NASDAQ: SGYP). All you have to do is sign up today for this free limited time offer by clicking the link below.
- Motley Fool•4 days ago
Buffett Gets Even Greedier With Teva Pharmaceuticals. Time to Buy?
America's favorite investor doubled down on a bet that this trainwreck isn't as bad as it looks. Should you follow?
- Investopedia•4 days ago
13F: Buffett Increased Apple, Monsanto & Teva
Warren Buffett, the billionaire investor and famed Oracle of Omaha, saw the stock portfolio of his Berkshire Hathaway decline by about $2 billion in Q1, according to recent filings with the SEC. The top five positions in Buffett's portfolio represent a whopping two thirds of the entire 13F investment package for the company. As of the end of March, AAPL was the largest portfolio stake for Berkshire Hathaway, accounting for more than 21% of the company's investments, according to its 13F filing.
- Zacks•5 days ago
Company News For May 17, 2018
Companies In The News are: FOXA,IQV,ABAX,ZTS,TEVA,BRK.B
Motley Fool•5 days agoThe Top Stocks Warren Buffett Is Buying Now
It might be smart to add these Berkshire Hathaway buys to your portfolio, too.
- Market Realist•5 days ago
Teva’s Fiscal Guidance: Confidence in Its Growth
Teva Pharmaceutical (TEVA) provided an increased guidance for this fiscal year during its first-quarter earnings release on May 3. The company has made an upward revision to its guidance for this fiscal year. Teva reported better-than-expected results in the fiscal first quarter.
- Benzinga•6 days ago
Warren Buffett Pushing More Cash To Equities; 'Big 5' Stocks Still At The Top
Warren Buffett’s Berkshire Hathaway Inc. (NYSE: BRK-A ) (NYSE: BRK-B ) filed its 13F for the first quarter on Tuesday, revealing what changes it made to its portfolio during the period. The company’s equity ...
- Reuters•6 days ago
Berkshire doubles Teva stake, adds to Apple, ends a newspaper bet
((Corrects ninth paragraph in May 15 article because of data error, and to show that Berkshire Hathaway is Apple's third-largest shareholder, trailing Vanguard Group and BlackRock, not its second-large) ...
Market Realist•6 days agoTeva’s Debt Reduction Plans Progress, Targets Are on Track
Teva Pharmaceutical (TEVA) has been working towards paying down the high level of debt on its balance sheet. Teva obtained the debt in 2016 to fund the acquisition of Allergan’s (AGN) generic business. At the end of fiscal 2017, Teva had a net debt of $31.5 billion on its balance sheet.
- InvestorPlace•6 days ago
Teva Pharmaceutical Industries Ltd, Once a Falling Machete, Is Spiking — Chase It
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) stock has been decimated over the years. This morning the stock is rallying on the news that the famed investor Warren Buffett doubled his stake in Teva stock. Wall Street loves to chase Buffett’s investments.
- Reuters•6 days ago
Berkshire doubles Teva stake, adds to Apple, ends a newspaper bet
Warren Buffett's Berkshire Hathaway Inc on Tuesday said it has more than doubled its investment in generic drugmaker Teva Pharmaceutical Industries Ltd , and confirmed it has become Apple Inc's second-largest ...
- Market Realist•6 days ago
Why Did Teva Stock Increase on May 14?
On May 14, Teva (TEVA) stock increased ~5.5% on the news of the expected delay in the FDA approval for rival Perrigo’s (PRGO) generic version of Teva’s asthma inhaler ProAir. On May 14, Teva stock closed at a trading price of $20.38 per share.
- Market Realist•6 days ago
Analysts’ Recommendations for AstraZeneca as of May 15
Analysts expect AstraZeneca (AZN) to report EPS (earnings per share) of $0.60 on revenue of $5.3 billion in the first quarter, a 2.3% fall compared to its revenue of $5.4 billion during the first quarter of 2017. AstraZeneca’s stock price has risen nearly 7.1% over the last 12 months and ~4.9% year-to-date.
- Zacks•6 days ago
Eli Lilly's Cluster Headache Candidate Succeeds in Phase III
Eli Lilly's (LLY) galcanezumab meets the primary endpoint in a late-stage study evaluating it for the prevention of episodic cluster headache.
- Investor's Business Daily•6 days ago
Stocks Inch Up, Dow Jones Lags; Boot Barn Spikes Out Of Buy Range
The Dow Jones industrials lagged Wednesday's early action as the market defended narrow gains. Teva, Macy's, Boot Barn and China's Tencent set up early leads.
- TheStreet.com•6 days ago
Teva Shares Jump After Warren Buffett Doubles Stake in Drugmaker
Warren Buffett's seal of approval was helping restructuring drugmaker Teva Pharmaceutical Industries Ltd. Teva's ADRs jumped 4.1% to $21.13 in early trading on Wednesday, May 16, after Buffett's Berkshire Hathaway Inc. Berkshire Hathaway increased its stake in Teva to 40.5 million shares, or about $692.8 million, as of the end of March, up from 18.9 million shares worth a total of $357.7 million as of the end of 2017.
Market Realist•6 days agoTeva Shares Rose on May 15, Berkshire Increased Its Stake
On May 15 after the market closed, Berkshire Hathaway (BRKB) published its holdings at the end of the first quarter as of March 31. According to the company’s SEC filings, it holds 40.5 million Teva Pharmaceutical (TEVA) shares as of March 31—compared to 19 million shares added during the fourth quarter of 2017, according to Berkshire’s filings as of December 31, 2017. At the time, Teva stock rose more than 10% following the news.
- Zacks•6 days ago
Teva Stock Up 5% as Buffett's Berkshire Raises Stake in Q1
Teva's (TEVA) shares gain 5% after Warren Buffett's Berkshire Hathaway reveals an increased stake in the company.
Market Realist•6 days agoHow Valeant Pharmaceuticals’ Branded Rx Segment Performed in 1Q18
In 1Q18, Valeant Pharmaceuticals (VRX) Branded Rx segment generated revenues of $593.0 million, compared to $629.0 million in 1Q17. This reflected ~6.0% growth on a year-over-year (or YoY) basis and an ~1.0% decline quarter-over-quarter.
- Investopedia•6 days ago
Buffett Buys More Apple and Teva Shares, Dumps IBM
Berkshire Hathaway doubles its stake in Teva, becomes Apple’s second-largest shareholder and exits its positions in IBM and Graham.
